## GLMN
- **UniProt:** Q92990 · **batch:** proteostasis-batch-2026-06-13 · **review status:** COMPLETE
- **PN placement:** `UPS|E3 ubiquitin and UBL ligases|CRL regulator|CRL inhibitor` ; **PN-node mapping:** type mapped, scope=ok_for_propagation_to_go, GO:1904667 negative regulation of ubiquitin protein ligase activity (group/class context_only; branch no_mapping)
- **Consistency:** Strong agreement across deep research (falcon, HIGH), review YAML, and dossier. Glomulin is a non-catalytic high-affinity RBX1-binding inhibitor (Kd ~38.6 nM, residues ~300-594) that masks the CDC34/E2 surface and inhibits CRL/SCF E3 activity, controlling FBXW7 turnover (Tron/Tron 2012 PMID:22405651; Duda 2012). Directionality (inhibitor) is consistent everywhere. All 33 GOA rows reviewed. No catalytic-ligase term assigned (correct).
- **PN story / NEW pressure:** The core inhibitory function is already well captured in GOA — GO:0055105 ubiquitin-protein transferase inhibitor activity (IBA+IGI, ACCEPT), GO:0031625 ubiquitin protein ligase binding, and CRL complex memberships. The review surfaces a genuine GO gap: the cIAP1/cIAP2-inflammasome axis (Suzuki 2018), proposed as a new term *without* an invented ID (correct). GO:0141086 negative regulation of inflammasome-mediated signaling pathway exists (verified real) and is a reasonable existing anchor for that proposed term.
- **Mapping strategy:** Sound. PN GO:1904667 (BP, negative regulation of ubiquitin protein ligase activity — verified) is the regulation-side counterpart of the review's MF GO:0055105; both are correct and complementary in directionality. Not over-broad like the TOMM20/HSPA8/RAB7A precedents — it is specifically the negative/inhibitor sense, matching the "CRL inhibitor" type.
- **Evidence alignment:** Convergent on the keystone paper: PN cites PMID:22405651, which is also the foundational, HIGH-relevance reference driving the review's core MF/BP/complex annotations. Review adds the older FAP48/FAP68 immunophilin and MET literature (8955134, 11164950, 11571281, 12604780, 11845407) as non-core, plus interactome PMIDs — all marked secondary; no conflict with the PN story.
- **Verdict:** Fully consistent; PN inhibitor mapping (GO:1904667) is well-aligned with the review (GO:0055105) — no over-reach, no missing-NEW pressure on the core function. **Recommended edits:** [YAML] optional — anchor the proposed "negative regulation of cIAP-mediated inflammasome activation" term to the now-existing GO:0141086 (verify scope) as the closest existing parent/match. No mapping change required.